Market Closed -
Nasdaq
21:00:00 26/04/2024 BST
|
5-day change
|
1st Jan Change
|
25.15
USD
|
+1.99%
|
|
-1.80%
|
+9.68%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
191.8
|
867.3
|
1,632
|
536.8
|
1,323
|
1,466
|
-
|
-
|
Enterprise Value (EV)
1 |
68.58
|
561.4
|
1,305
|
411
|
1,136
|
1,078
|
828.2
|
1,466
|
P/E ratio
|
-2.37
x
|
-10.5
x
|
-12.6
x
|
-4.2
x
|
-16.5
x
|
35.1
x
|
-31.1
x
|
-31.3
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
830
x
|
30.3
x
|
59.7
x
|
20.2
x
|
22
x
|
7.06
x
|
12.2
x
|
10.1
x
|
EV / Revenue
|
297
x
|
19.6
x
|
47.7
x
|
15.5
x
|
18.9
x
|
5.19
x
|
6.91
x
|
10.1
x
|
EV / EBITDA
|
-
|
-8.81
x
|
-10.4
x
|
-
|
-12.3
x
|
-7.49
x
|
9.41
x
|
-
|
EV / FCF
|
-1.62
x
|
-7.7
x
|
-12
x
|
-3.77
x
|
-16
x
|
6.09
x
|
-24
x
|
-18.8
x
|
FCF Yield
|
-61.8%
|
-13%
|
-8.35%
|
-26.5%
|
-6.24%
|
16.4%
|
-4.17%
|
-5.32%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
27,206
|
43,019
|
47,728
|
49,198
|
57,678
|
58,275
|
-
|
-
|
Reference price
2 |
7.050
|
20.16
|
34.20
|
10.91
|
22.93
|
25.15
|
25.15
|
25.15
|
Announcement Date
|
10/03/20
|
10/03/21
|
28/02/22
|
15/03/23
|
27/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.231
|
28.63
|
27.36
|
26.58
|
60
|
207.5
|
119.8
|
145.6
|
EBITDA
1 |
-
|
-63.73
|
-125
|
-
|
-92.68
|
-144
|
88
|
-
|
EBIT
1 |
-80.52
|
-64.52
|
-125.8
|
-131.4
|
-93.65
|
40.67
|
-6.928
|
-44.08
|
Operating Margin
|
-34,857.58%
|
-225.36%
|
-460.01%
|
-494.24%
|
-156.09%
|
19.6%
|
-5.78%
|
-30.27%
|
Earnings before Tax (EBT)
1 |
-77.88
|
-64.84
|
-125.6
|
-127.4
|
-78.96
|
83.42
|
1.034
|
-45.28
|
Net income
1 |
-77.19
|
-66.15
|
-125.6
|
-127.4
|
-78.96
|
44.95
|
-6.793
|
-47.46
|
Net margin
|
-33,414.29%
|
-231.07%
|
-458.94%
|
-479.26%
|
-131.59%
|
21.66%
|
-5.67%
|
-32.59%
|
EPS
2 |
-2.980
|
-1.920
|
-2.710
|
-2.600
|
-1.390
|
0.7174
|
-0.8096
|
-0.8033
|
Free Cash Flow
1 |
-42.4
|
-72.96
|
-109
|
-108.9
|
-70.84
|
177
|
-34.5
|
-78
|
FCF margin
|
-18,355.41%
|
-254.84%
|
-398.31%
|
-409.81%
|
-118.08%
|
85.3%
|
-28.8%
|
-53.57%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
393.78%
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/03/20
|
10/03/21
|
28/02/22
|
15/03/23
|
27/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
10.29
|
8.617
|
25.72
|
0.859
|
-
|
-
|
-
|
-
|
-
|
60
|
120
|
60
|
-
|
9
|
-
|
EBITDA
1 |
-33.71
|
-36.78
|
-20.86
|
-41.18
|
-32.03
|
-36.26
|
-35.77
|
-42.12
|
-38.08
|
23.3
|
-38
|
-38
|
-39
|
-30
|
-
|
EBIT
1 |
-33.93
|
-37.02
|
-21.11
|
-41.44
|
-32.3
|
-36.52
|
-36.02
|
-42.35
|
-38.33
|
23.05
|
36.92
|
30.55
|
-40.6
|
-30.75
|
-
|
Operating Margin
|
-329.83%
|
-429.57%
|
-82.07%
|
-4,824.56%
|
-
|
-
|
-
|
-
|
-
|
38.42%
|
30.77%
|
50.92%
|
-
|
-341.67%
|
-
|
Earnings before Tax (EBT)
1 |
-33.8
|
-36.91
|
-20.93
|
-41.04
|
-31.23
|
-34.19
|
-33.72
|
-38.46
|
-34.1
|
27.34
|
114.2
|
-37.05
|
-38.4
|
-16.75
|
-
|
Net income
1 |
-33.8
|
-36.91
|
-20.93
|
-41.04
|
-31.23
|
-34.19
|
-33.72
|
-38.46
|
-34.1
|
27.34
|
39.32
|
32.35
|
-38.44
|
-28.12
|
-
|
Net margin
|
-328.64%
|
-428.3%
|
-81.37%
|
-4,777.3%
|
-
|
-
|
-
|
-
|
-
|
45.56%
|
32.77%
|
53.91%
|
-
|
-312.44%
|
-
|
EPS
2 |
-0.7000
|
-0.7700
|
-0.4300
|
-0.8400
|
-0.6400
|
-0.6900
|
-0.6700
|
-0.6800
|
-0.5800
|
0.4400
|
1.194
|
0.3360
|
-0.6341
|
-0.5051
|
-0.7700
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
03/11/21
|
28/02/22
|
04/05/22
|
04/08/22
|
08/11/22
|
15/03/23
|
04/05/23
|
03/08/23
|
02/11/23
|
27/02/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
123
|
306
|
327
|
126
|
187
|
388
|
637
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-42.4
|
-73
|
-109
|
-109
|
-70.8
|
177
|
-34.5
|
-78
|
ROE (net income / shareholders' equity)
|
-
|
-36.8%
|
-43.3%
|
-49.4%
|
-28.6%
|
-49.5%
|
16.7%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-27.6%
|
-37.4%
|
-42.8%
|
-26.1%
|
-39.6%
|
15.1%
|
-
|
Assets
1 |
-
|
239.7
|
336.1
|
297.8
|
302.9
|
-113.6
|
-44.97
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.97
|
0.47
|
1.1
|
0.8
|
0.61
|
-
|
-
|
-
|
Capex / Sales
|
418.61%
|
1.65%
|
4.02%
|
2.99%
|
1.02%
|
-
|
-
|
-
|
Announcement Date
|
10/03/20
|
10/03/21
|
28/02/22
|
15/03/23
|
27/02/24
|
-
|
-
|
-
|
Last Close Price
25.15
USD Average target price
43
USD Spread / Average Target +70.97% Consensus |
1st Jan change
|
Capi.
|
---|
| +9.68% | 1.47B | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|